1. Home
  2. SNT vs IFRX Comparison

SNT vs IFRX Comparison

Compare SNT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senstar Technologies Ltd.

SNT

Senstar Technologies Ltd.

HOLD

Current Price

$3.33

Market Cap

95.2M

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.06

Market Cap

86.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNT
IFRX
Founded
1965
2007
Country
Canada
Germany
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.2M
86.0M
IPO Year
1993
2017

Fundamental Metrics

Financial Performance
Metric
SNT
IFRX
Price
$3.33
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
64.2K
6.5M
Earning Date
11-25-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
257.88
N/A
EPS
0.21
N/A
Revenue
$37,837,000.00
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,075.42
P/E Ratio
$13.70
N/A
Revenue Growth
9.82
N/A
52 Week Low
$2.57
$0.71
52 Week High
$5.34
$2.77

Technical Indicators

Market Signals
Indicator
SNT
IFRX
Relative Strength Index (RSI) 37.41 43.05
Support Level $2.75 $0.92
Resistance Level $3.93 $1.12
Average True Range (ATR) 0.37 0.10
MACD -0.11 -0.02
Stochastic Oscillator 31.27 39.73

Price Performance

Historical Comparison
SNT
IFRX

About SNT Senstar Technologies Ltd.

Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: